Pharmacopeia and CV Thera sign cardio discovery deal

Under the terms of the agreement, Pharmacopeia is employing its comprehensive, integrated drug discovery platform and discovery expertise that has, to date, resulted in four programs advancing into human clinical trials with its partners.

CV Therapeutics will be responsible for development and marketing of collaboration products, and will bring its pharmacology and clinical expertise and experience to the collaboration.

Pharmacopeia will receive research funding in addition to clinical milestones and royalties if and when the collaboration products advance through clinical development and onto the market.

“Working with collaborators in therapeutic segments outside of Pharmacopeia’s internal discovery focus on immunological diseases extracts maximum value from the company’s drug discovery platform, which is therapeutic area agnostic,” said Dr Les Browne, president and CEO of Pharmacopeia.

“CV Therapeutics is an innovator in molecular cardiology and cardiovascular disease and therefore an excellent choice of partner for Pharmacopeia. I am delighted to have this collaboration underway,” he continued.